Barclays
ELTX icon

Barclays’s Elicio Therapeutics ELTX Stock Holding History

Barclays’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-362
Closed -$2.1K – 4679
2023
Q1 		$2.1K Hold
362
– – ﹤0.01% 4887
2022
Q4 		$2.94K Hold
362
– – ﹤0.01% 5057
2022
Q3 		$3K Hold
362
– – ﹤0.01% 4576
2022
Q2 		$4K Sell
362
-353
-49% -$5.64K ﹤0.01% 4811
2022
Q1 		$15K Buy
+715
New +$16.1K ﹤0.01% 4516

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MHC
Meyer Handelman Company Rye Brook, New York $3.22B AUM 24.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Barclays's ELTX Position: Q2 2023 in Review

Barclays sold out of Elicio Therapeutics (ELTX) in Q2 2023, closing a stake of 362 shares — an estimated $2.1K sold.

Barclays first reported a position in ELTX in Q1 2022 and held it in 5 quarters. The position peaked at $15K in Q1 2022. 15 funds tracked by Wall St. Rank hold ELTX as of Q2 2023.

  • Barclays reported no remaining Elicio Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 362 Elicio Therapeutics shares in Q2 2023, an estimated $2.1K.
  • Barclays first reported a position in Elicio Therapeutics in Q1 2022 and held it in 5 quarters.
  • Barclays's Elicio Therapeutics position peaked at $15K in Q1 2022.
  • 15 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.